Technology Transfer: Moving a Process Without Moving the Product

Technology transfer moves a manufacturing process from one site to another: development to commercial, site to site, or in-house to a contract manufacturer. ICH Q10 treats it as a lifecycle stage rather than a project.

The obligation is not to move the process. It is to demonstrate the product is unchanged, which is a harder and more evidential thing.

What actually transfers

The batch record is the visible part and the smallest.

• The process and its parameters, with the ranges and the reasoning behind them.
• The control strategy: what is controlled where, and why that combination assures quality.
• Analytical methods, which need their own transfer and their own verification at the receiving site.
• Specifications, and the justification for each.
• Development history, including what was tried and rejected. This is what stops the receiving site re-learning by failure.
• Deviation and investigation history for the process.
• Materials, including supplier qualification status, which does not automatically carry across.

The development history is the part most often left behind, and its absence is why a receiving site repeats a failure the sending site solved years ago.

Comparability decides the outcome

The evidence that the product is unchanged.

For small molecules, comparability is typically demonstrated through batch analysis against specification, process performance, and stability at the new site.

For biologics it is substantially harder. The process defines the product, and an analytical comparability exercise covering structure, purity, potency and impurity profile is expected. Where analytical comparability is insufficient, clinical data can be required, which is the risk that makes biologics site changes strategic rather than operational.

The regulatory consequence runs in parallel

A site change is a reportable change, and the category depends on what moved and what the data show. For a marketed product this needs deciding early, because a prior approval supplement means you cannot ship from the new site until FDA agrees.

If the receiving site is a contract facility, the quality agreement has to be in place before transfer, not after, and the site's own inspection history is public and checkable.

Where transfers go wrong

Tacit knowledge stays behind. The operator who knows the granulation needs an extra minute in humid weather. Nothing in the batch record captures it.

Equipment is equivalent on paper. Same nominal capacity, different geometry, different shear. Scale and equipment differences are the usual root cause of a transfer that will not reproduce.

Analytical methods transfer late, so the receiving site cannot test its own batches and the comparability exercise stalls.

The regulatory strategy follows the technical work instead of running with it, and the site is ready months before it can ship.